Summary

Global Branded Generics Market was valued at USD 261.41 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.20% through 2030. Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The rising prevalence of chronic diseases is a major driving force behind the expansion of the Global Branded Generics Market. Approximately 9 million people succumb to cancer annually, while 4 million deaths are attributed to chronic respiratory diseases like asthma and COPD, and another 2 million result from diabetes-related complications. However, the global distribution of disease burden and access to advanced healthcare solutions remains highly uneven, with disparities particularly evident in low- and middle-income regions where medical infrastructure, early diagnostics, and treatment accessibility are significantly limited. With a growing global disease burden, healthcare systems and consumers are increasingly turning to cost-effective and reliable treatment options, making branded generics a preferred choice. Chronic diseases such as cardiovascular diseases (CVDs), diabetes, cancer, respiratory disorders, and arthritis are becoming more prevalent due to factors such as aging populations, unhealthy lifestyles, and environmental changes. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for nearly 74% of all global deaths, highlighting the urgent need for long-term treatment solutions. Increased demand for continuous medication supply for long-term disease management. Greater emphasis on cost-effective treatment alternatives, making branded generics a viable solution. Higher healthcare spending by governments and private insurers to address chronic disease care.
Key Market Challenges
Regulatory Hurdles
Generic medications, including branded generics, need to go through regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.
Key Market Trends
Advancements in Digital Health Integration
Digital health technologies can improve patient engagement by providing tools for medication reminders, tracking, and adherence. Branded generics, as more affordable alternatives, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for chronic disease management. Digital health solutions enable remote monitoring of patients' health conditions, which is particularly useful for managing chronic diseases. This integration can enhance patient compliance with medication regimens, contributing to the growth of the market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics. Branded generics can be tailored to fit individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can improve awareness of branded generics among patients and healthcare providers. Through digital platforms, manufacturers can educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can use data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns. This information can guide marketing strategies and product positioning for branded generics.
Key Market Players
• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sanofi-Aventis.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.
Report Scope:
In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Branded Generics Market, By Drug Class:
o Alkylating Agents
o Antimetabolites
o Hormones
o Anti – Hypertensive
o Lipid Lowering Drugs
o Antidepressant
o Antipsychotics
o Antiepileptics
o Others
• Branded Generics Market, By Application:
o Oncology
o Cardiovascular Diseases
o Neurological Diseases
o Acute & Chronic Pain
o Gastrointestinal Diseases
o Dermatological Diseases
o Others
• Branded Generics Market, By Distribution Channel:
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• Branded Generics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.
Available Customizations:
Global Branded Generics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Branded Generics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
5.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Branded Generics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
6.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Branded Generics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Application
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Branded Generics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Application
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Branded Generics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Application
6.3.3.2.3. By Distribution Channel
7. Europe Branded Generics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Application
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Branded Generics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Application
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Branded Generics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Application
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Branded Generics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Application
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Branded Generics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Application
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Branded Generics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Application
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Branded Generics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Application
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Branded Generics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Application
8.3.1.2.3. By Distribution Channel
8.3.2. India Branded Generics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Application
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Branded Generics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Application
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Branded Generics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Application
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Branded Generics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Application
8.3.5.2.3. By Distribution Channel
9. South America Branded Generics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Application
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Branded Generics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Application
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Branded Generics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Application
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Branded Generics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Application
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Branded Generics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Application
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Branded Generics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Application
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Branded Generics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Application
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Branded Generics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Application
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Branded Generics Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Teva Pharmaceutical Industries Ltd.
15.1.1. Business Overview
15.1.2. Product & Service Offerings
15.1.3. Recent Developments
15.1.4. Financials (If Listed)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Lupin Pharmaceuticals Inc.
15.3. Sanofi-Aventis.
15.4. Sun Pharmaceutical Industries Inc.
15.5. Dr Reddy's Laboratories Inc.
15.6. Endo International PLC.
15.7. GlaxoSmithKline LLC.
15.8. Pfizer Inc.
15.9. Viatris Inc.
15.10. Apotex Inc.
16. Strategic Recommendations
17. About Us & Disclaimer